{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"33","value":"102"},{"groupId":"OG002","spread":"17.3","value":"68.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"20"}],"units":"Participants"}],"title":"Cycle 1, NSCLC patients"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"36.5","value":"118"},{"groupId":"OG002","spread":"24.2","value":"100"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"13"}],"units":"Participants"}],"title":"Cycle 3, NSCLC patients"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"25.2","value":"75.7"},{"groupId":"OG002","spread":"26.2","value":"71.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"20"}],"units":"Participants"}],"title":"Cycle 1, melanoma patients"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"29.8","value":"117"},{"groupId":"OG002","spread":"43.3","value":"105"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"14"}],"units":"Participants"}],"title":"Cycle 3, melanoma patients"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.3","value":"81"},{"groupId":"OG002","spread":"25.8","value":"67"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"15"}],"units":"Participants"}],"title":"Cycle 1, RCC patients"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"23.8","value":"104"},{"groupId":"OG002","spread":"36.1","value":"103"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"13"}],"units":"Participants"}],"title":"Cycle 3, RCC patients"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.4","value":"70.5"},{"groupId":"OG002","spread":"39","value":"82.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"35"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"16"}],"units":"Participants"}],"title":"Cycle 1, mesothelioma patients"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"31.5","value":"96.5"},{"groupId":"OG002","spread":"36.8","value":"113"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"16"}],"units":"Participants"}],"title":"Cycle 3, mesothelioma patients"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"25.1","value":"91.5"},{"groupId":"OG001","spread":"36.7","value":"117"},{"groupId":"OG002","spread":"14.8","value":"89.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"19"},{"groupId":"OG002","value":"13"}],"units":"Participants"}],"title":"Cycle 1, TNBC patients"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"36.5","value":"124"},{"groupId":"OG001","spread":"54","value":"134"},{"groupId":"OG002","spread":"18.5","value":"123"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"9"}],"units":"Participants"}],"title":"Cycle 3, TNBC patients"}],"denoms":[{"counts":[{"groupId":"OG000","value":"121"},{"groupId":"OG001","value":"21"},{"groupId":"OG002","value":"92"}],"units":"Participants"}],"description":"Pharmacokinetic (PK) parameters were calculated based on PDR001 serum concentrations by using non-compartmental methods. Cmax is defined as the maximum (peak) observed serum concentration following a dose.","dispersionType":"Standard Deviation","groups":[{"description":"Combination LAG525 400 mg + PDR001 300 mg (Q3W/Q3W) in patients naïve to anti-PD-1/PD-L1","id":"OG000","title":"Phase 2: Naive - LAG525 400 mg Q3W + PDR001 300 mg Q3W"},{"description":"Combination LAG525 600 mg + PDR001 400 mg (Q4W/Q4W) in patients naïve to anti-PD-1/PD-L1","id":"OG001","title":"Phase 2: Naive - LAG525 600 mg Q4W + PDR001 400 mg Q4W"},{"description":"Combination LAG525 400 mg + PDR001 300 mg (Q3W/Q3W) in patients pre-treated with anti-PD-1/PD-L1","id":"OG002","title":"Phase 2: Pre-treated - LAG525 400 mg Q3W + PDR001 300 mg Q3W"}],"paramType":"MEAN","populationDescription":"All patients in phase 2 who received at least one full or partial dose of PDR001 and who had at least one serum sample providing evaluable PK data.","reportingStatus":"POSTED","timeFrame":"pre-infusion, 1, 24, 168, 240 and 336 hours post-infusion, and 504 hours (Q3W regimens only) and 672 hours (Q4W regimens only) post infusion on Cycle 1 Day 1 and Cycle 3 Day 1. The duration of one cycle was 21 days (Q3W) and 28 days (Q4W).","title":"Phase 2: Maximum Observed Serum Concentration (Cmax) of PDR001","type":"SECONDARY","unitOfMeasure":"ug/mL"}